Curated News
By: NewsRamp Editorial Staff
October 15, 2026
hyperCORE International Elects New Officers to Drive Growth
TLDR
- hyperCORE International elected new officers, giving CROs a single connection to over 50 sites and faster trial access.
- hyperCORE International elected Jeffrey Smyth as President and other officers to support its strategic scaling platform for clinical research.
- hyperCORE International's new leadership will help clinical research sites grow and give patients better access to trials.
- hyperCORE International elected new officers, offering CROs feasibility in 48 to 72 hours across 25 therapeutic areas.
Impact - Why it Matters
This leadership transition signals stability and ambition for hyperCORE International, which occupies a unique niche in the clinical research ecosystem. As drug development grows more complex and costly, the ability to quickly connect sponsors and CROs with qualified sites and diverse patient populations is critical. hyperCORE’s model addresses this by aggregating independent site networks under one strategic umbrella, potentially speeding up trial timelines and improving access to cutting-edge therapies for patients. The new officers’ expertise will be crucial in scaling these efforts, ultimately impacting how efficiently new treatments reach the market. For sites, it means greater support without losing autonomy; for CROs, it offers a streamlined path to the right patients. This news matters because it reflects a broader trend of consolidation and partnership in research, which can drive innovation and improve health outcomes.
Summary
hyperCORE International, a strategic scaling platform for clinical research sites, announced new officers on October 15, 2026. Jeffrey Smyth was elected President, Seneca Harrison as Vice President, Claxton Copeland as Secretary, and Dustin Owen continues as Treasurer. These appointments reinforce hyperCORE’s dual mission: helping site networks grow while preserving independence, and giving CROs a single strategic connection to a high-performing network. Smyth expressed gratitude and excitement for scaling impact, while former President Nicholas Focil emphasized that strong leadership is key to helping partners scale.
For site networks, hyperCORE provides resources and relationships to accelerate growth without sacrificing autonomy. Current partners include Empathx Clinical Research, FOMAT Medical Research, Optimal Research Sites, QCR Network, and TrueBlue Clinical Research. Alumni feature Lynd Clinical, Avacare, Flourish Research, Centricity Research, and Alcanza Clinical Research. For CROs, hyperCORE streamlines access through one point of contact, offering 48- to 72-hour feasibility turnaround, broad U.S. reach, and expanded patient access via more than 50 sites, 120+ principal investigators, and experience across 25+ therapeutic areas and multiple trial phases, with access to over 3.4 million patients.
Source Statement
This curated news summary relied on content distributed by 24-7 Press Release. Read the original source here, hyperCORE International Elects New Officers to Drive Growth
